Despite 30 years of study, there is no HIV-1 vaccine and, until recently, there was little hope
for a protective immunization. Renewed optimism in this area of research comes in part from …

Despite 30 years of effort, there is no effective vaccine for HIV-1. However, antibodies can
prevent HIV-1 infection in humanized mice and macaques when passively transferred. New …

Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …

The Omicron variant of SARS-CoV-2 is causing a rapid increase in infections across the
globe. This new variant of concern carries an unusually high number of mutations in key …

Background While the leading symptoms during coronavirus disease 2019 (COVID-19) are
acute and the majority of patients fully recover, a significant fraction of patients now …

Passive transfer of broadly neutralizing HIV antibodies can prevent infection, which suggests
that vaccines that elicit such antibodies would be protective. Thus far, however, few broadly …

Background Heterologous vaccine regimens have been widely discussed as a way to
mitigate intermittent supply shortages and to improve immunogenicity and safety of COVID …

Objectives Patients with acute respiratory distress syndrome (ARDS) due to viral infection
are at risk for secondary complications like invasive aspergillosis. Our study evaluates …

HIV-1 immunotherapy with a combination of first generation monoclonal antibodies was
largely ineffective in pre-clinical and clinical settings and was therefore abandoned …

Human immunodeficiency virus type 1 (HIV-1)-specific monoclonal antibodies with
extraordinary potency and breadth have recently been described. In humanized mice …